通过小分子抗剂抑制 lysosomal 双孔通道 TPC2 的结构基础

Gamma Chi1, Dawid Jaślan2, Veronika Kudrina2

  • 1Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK.

概括

药物SG-094是一种强大的双孔通道2 (TPC2) 抑制剂,与TPC2不对称地结合,阻断了通道功能. 这一发现为癌症和埃博拉和COVID-19等病毒性疾病提供了新的治疗策略.